Sarepta Shares Community Letter Regarding ELEVIDYS Label Update

November 18, 2025

On November 16, 2025, Sarepta Therapeutics Inc. shared a Community Letter with updates regarding the label for ELEVIDYS, Sarepta’s approved gene therapy for Duchenne muscular dystrophy.

To view Sarepta’s Community Letter, please click here

Jett Foundation’s Silver Soirée
Thursday, June 11, 2026 | 5:30PM
Granite Links | Quincy, MA